Diabetes und Herz

• Literatur

• 1 Saeedi P, Petersohn I, Salpea P. et al Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes research and clinical practice 2019; 157: 107843
• 2 [Anonym]. WHO European Regional Obesity Report 2022. In https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-eng.pdf 2022
• 3 Lind M, Svensson A-M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2015; 372: 880-881
• 4 Schütt K, Forst T, Birkenfeld AL. et al Diabetes Mellitus and the Heart. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
• 5 Collaboration TERF. Association of Cardiometabolic Multimorbidity With Mortality. JAMA 2015; 314: 52-60
• 6 Shah AD, Langenberg C, Rapsomaniki E. et al Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. The Lancet Diabetes & Endocrinology 2015; 03: 105-113
• 7 Fernandez CJ, George AS, Subrahmanyan NA. et al Epidemiological link between obesity, type 2 diabetes mellitus and cancer. World J Methodol 2021; 11: 23-45
• 8 Keen H. The Diabetes Control and Complications Trial (DCCT). Health Trends 1994; 26: 41-43
• 9 Group US. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
• 10 Dormandy JA, Charbonnel B, Eckland DJ. et al Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289